Bayer continues to make progress on its five-point plan to manage and mitigate the risks of Roundup™ litigation in the U.S. We settled most of the claims in this litigation and have appropriately provisioned for the remaining claims. Having won most trials, the company will continue to try cases based on decades of science and worldwide regulatory assessments that continue to support Roundup’s safety and non-carcinogenicity.